Pfizer Eyes GLP-1 Market Entry by 2028: What the Metsera Deal Means for Investors
Pfizer has confirmed plans to enter the lucrative GLP-1 obesity drug market by 2028, following its acquisition of Metsera. The move positions the pharmaceutical giant to compete directly with Novo Nordisk and Eli Lilly in a sector projected to exceed $100 billion in annual revenue. For investors, the timeline and strategic rationale carry significant implications for PFE stock valuation.
ViaNews Editorial Team (Markets)•